Thin basement membrane disease cost-effectiveness of therapy: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Thin basement membrane disease}} | {{Thin basement membrane disease}} | ||
{{CMG}} | |||
{{AE}} {{MMT}} | |||
==Overview== | ==Overview== |
Latest revision as of 09:36, 21 December 2020
Thin basement membrane disease Microchapters |
Differentiating Thin basement membrane disease from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Thin basement membrane disease cost-effectiveness of therapy On the Web |
American Roentgen Ray Society Images of Thin basement membrane disease cost-effectiveness of therapy |
FDA on Thin basement membrane disease cost-effectiveness of therapy |
CDC on Thin basement membrane disease cost-effectiveness of therapy |
Thin basement membrane disease cost-effectiveness of therapy in the news |
Blogs on Thin basement membrane disease cost-effectiveness of therapy |
Directions to Hospitals Treating Thin basement membrane disease |
Risk calculators and risk factors for Thin basement membrane disease cost-effectiveness of therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Marufa Marium, M.B.B.S[2]
Overview
The cost of the supportive therapy for symptoms are not very expensive except long term dialysis and renal transplantation.
Cost-effectiveness
The cost-effectiveness of the supportive therapy for symptoms are not very costly. But patient with Renal impairment or renal failure should be counselled on cost of a long tern dialysis or renal transplantation. Moreover, the frequency of screening procedures may cause burden to a patient or the family's physical and mental health. The importance of early diagnosis and treatment should be explained in meaningful way.